Medline Inc. Class A common stock

Medline's 50.7 P/E ratio stands nearly double the median for surgical instrument manufacturers, yet the stock sits at a relatively neutral RSI of 48 with only 4.79% short interest—suggesting neither euphoric momentum nor significant skepticism from bears. The $37B market cap reflects a premium valuation despite not being at 52-week highs, implying the market has already priced in substantial growth expectations. This disconnect between stretched multiples and lack of overbought technicals creates an interesting tension: either fundamentals justify the premium, or the stock has room to compress if growth disappoints. The modest short positioning leaves limited squeeze potential, while the RSI reveals no imminent reversal signals in either direction.